Potent Sedative Medetomidine Detected in Illegal Drug Supply, Posing New Overdose and Withdrawal Risks

The U.S. Centers for Disease Control and Prevention (CDC), in collaboration with the White House Office of National Drug Control Policy (ONDCP), has issued a health advisory warning of an escalating threat: the increasing presence of medetomidine in the illicit drug supply. This veterinary sedative, also known by street names such as “rhino tranq” or “mede,” is being detected in drug seizures and samples across the nation, with a notable concentration in the Northeast region. Medetomidine is not approved for human use and its presence, often in racemic mixtures of its isomers without typical pharmaceutical preservatives, suggests clandestine synthesis rather than diversion from medical or veterinary sources. This development raises significant concerns for public health professionals, clinicians, and individuals at risk of overdose.

The inclusion of medetomidine in the illegal drug supply introduces a complex set of risks. When used, medetomidine can induce profound sedation, a slowed heart rate (bradycardia), and dangerously low blood pressure (hypotension). Compounding these dangers, individuals who regularly use drugs containing medetomidine may experience severe withdrawal symptoms if they stop. These symptoms can be particularly challenging and include dangerously high blood pressure (hypertension), intense anxiety, nausea, vomiting, and fluctuations in alertness, potentially requiring emergency medical intervention or intensive care. The CDC advises that given the frequent co-occurrence of medetomidine with fentanyl in overdose cases, opioid overdose reversal medications, such as naloxone, remain crucial for addressing respiratory depression and restoring normal breathing in suspected overdoses.

Public health officials are urged to utilize syndromic surveillance systems to identify potential cases of medetomidine intoxication or withdrawal symptoms within their communities. A collaborative approach between public health agencies, law enforcement, and healthcare providers is essential for monitoring the local drug supply and disseminating timely information. This shared intelligence will help to align public health responses and clinical care strategies. Clinicians are encouraged to consider medetomidine as a potential factor in suspected opioid overdoses, particularly when sedation is prolonged and unresponsive to naloxone. In such instances, consulting a toxicologist or poison control center at 1-800-222-1222 is recommended, along with reporting unusual cases to the relevant health department.

Article by Mel Anara, based upon information from the U.S. Centers for Disease Control and Prevention (CDC)

Video Spotlight